LIB Therapeutics Presents LEROCHOL� Data at Cardiology Conference

The biopharmaceutical company shared results from its new cholesterol treatment at the 2026 American College of Cardiology meeting.

Mar. 30, 2026 at 6:08pm

Got story updates? Submit your updates here. ›

LIB Therapeutics, a privately-held biopharmaceutical company, announced the presentation of data on its recently approved novel cholesterol treatment LEROCHOL� at the 2026 American College of Cardiology annual meeting. LEROCHOL� is a monthly, small-dose third-generation cholesterol medication developed by LIB Therapeutics.

Why it matters

The presentation of LEROCHOL� data at a major cardiology conference signals the company's efforts to introduce a new treatment option for patients struggling with high cholesterol, a leading risk factor for heart disease. As the healthcare industry continues to seek more effective and convenient cholesterol management solutions, LIB's novel approach could provide an alternative for those who have difficulty adhering to daily oral medications.

The details

LIB Therapeutics is a privately-held biopharmaceutical company that recently received approval for its new cholesterol treatment LEROCHOL�. The company presented data on LEROCHOL� at the 2026 American College of Cardiology annual meeting, highlighting the medication's novel monthly dosing and small dosage compared to existing cholesterol drugs.

  • The 2026 American College of Cardiology annual meeting took place in March 2026.

The players

LIB Therapeutics Inc.

A privately-held biopharmaceutical company that recently received approval for its novel cholesterol treatment LEROCHOL�.

LEROCHOL�

A monthly, small-dose third-generation cholesterol medication developed by LIB Therapeutics.

Got photos? Submit your photos here. ›

The takeaway

LIB Therapeutics' presentation of LEROCHOL� data at the American College of Cardiology meeting highlights the company's efforts to introduce a new cholesterol management option that could provide a more convenient and effective alternative for patients struggling with high cholesterol.